VISTASEAL is a fibrin sealant for surgical bleeding-control that combines two plasma proteins (fibrinogen and thrombin) administered with Ethicon’s airless spray device technology.
The collaboration combines Grifols’ ability to produce critical plasma-based therapies with Ethicon’s expertise in developing device technology. Ethicon, a Johnson & Johnson Medical Devices Company, is commercializing and distributing VISTASEAL in the United States.
Eduardo Herrero, president Grifols Bioscience Industrial Group, said: “VISTASEAL is the result of our continuous efforts to innovate and a commitment to in-house R&D projects. We will continue to investigate and explore different areas of medicine with unmet needs in which plasma proteins can add value. In this sense, biosurgery is a field full of potential for us in which we count on a sound, strategic ally in Ethicon.”
The VISTASEAL biological components are produced in the industrial complex of Parets del Vallés (Barcelona, Spain), which has a production capacity of over 300,000 units, as well as capacity to expand to 3 million equivalent liters of plasma.
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions—Bioscience, Diagnostic, Hospital and Bio Supplies—develop, produce, and market solutions and services that are sold in more than 100 countries.
Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.
The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35. Grifols non-voting class B shares are listed on the Mercado Continuo and on the U.S. NASDAQ through ADRs.